GlassScriptPhysician profile
Heidi Wagner
NPI 1689749483
$6,675.49
in general payments reported to CMS, 2019-2025
13 companies · $842 in 2025
The $842 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $26.31 · 2021: $416 · 2022: $276 · 2023: $3,200 · 2024: $856 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,500 · Food and Beverage: $1,099 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,500.00 |
| Food and Beverage | $1,098.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $3,486.53 | 2019-2025 | Misight Contact Lens, Clariti Contact Lens, Ortho-K Contact Lens |
| Alcon Vision LLC | $1,081.18 | 2019-2025 | Air Optix, Dailies Total1, Precision 1 |
| Johnson & Johnson Vision Care, INC. | $559.06 | 2019-2025 | Acuvue |
| Glaukos Corporation | $552.72 | 2023-2025 | Kxl System (Not Refurbished), Ce-Marked Kxla System, Kxl System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $283.22 | 2019-2021 | |
| Visioneering Technologies, INC. | $159.83 | 2019 | |
| Bausch & Lomb Americas INC. | $130.73 | 2024-2025 | Alden Scleral Zenlens, Blink Nutritears, Alden Corneal Gp |
| Lombart Brothers, INC. | $129.01 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $109.30 | 2024 | |
| Dompe US, INC. | $71.27 | 2022-2025 | Oxervate |
| Allergan, INC. | $54.74 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $40.26 | 2025 | |
| Astellas Pharma US INC | $17.64 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.